A novel molecule originated by Japanese academia has recorded an unusual success in a Phase II trial for a challenging dermatologic oncology indication, and appears to be the only drug globally in its class to be in active clinical development.
Japan Academia Progresses Novel Melanoma Drug Despite Pharma 'Reluctance'
Promising Phase II Results
Academia-developed novel oral PAI-1 inhibitor in combination with Opdivo showed a strong response rate in PD-1 treated melanoma patients with certain disease characteristics and could represent a new breakthrough for a class with no clinical stage competitors.
